SEC Comment Letter for MetaVia Inc. (MTVA) (CIK 0001638287) (MTVA) — Apr 18, 2017
MetaVia Inc. (MTVA) (CIK 0001638287)
Date: April 18, 2017 · CIK: 0001638287 · Accession: 0000000000-17-013320
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-217296
Letter
Mail Stop 4546 April 18, 2017 Mina Sooch Chief Executive Officer Gemphire Therapeutics Inc. 17199 N. Laurel Park Drive, Suite 401 Livonia, Michigan 48152
Re: Gemphire Therapeutics Inc. Registration Statement on Form S-1 Filed April 13, 2017 File No. 333-217296
Dear Ms. Sooch :
This is to advise you that we have not reviewed and will not review your registration statement .
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at (202) 551 -6761 with any questions.
Sincerely,
/s/ Mary Beth Breslin for
Show Raw Text
Mail Stop 4546 April 18, 2017 Mina Sooch Chief Executive Officer Gemphire Therapeutics Inc. 17199 N. Laurel Park Drive, Suite 401 Livonia, Michigan 48152 Re: Gemphire Therapeutics Inc. Registration Statement on Form S-1 Filed April 13, 2017 File No. 333-217296 Dear Ms. Sooch : This is to advise you that we have not reviewed and will not review your registration statement . Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551 -6761 with any questions. Sincerely, /s/ Mary Beth Breslin for Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Meredith Ervine, Esq. Honigman Miller Schwartz and Cohn LLP